Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atigotatug + nivolumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BMS-986489 is a fixed-dose combination (FDC) of atigotatug, a monoclonal antibody targeting T-cell immunoreceptor with Ig and ITIM domains (TIGIT), and nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor. Developed by Bristol Myers Squibb, this combination aims to enhance anti-tumor immune responses by simultaneously blocking two distinct inhibitory pathways on T cells and natural killer (NK) cells. TIGIT is an inhibitory receptor expressed on various immune cells that competes with the activating receptor CD226 for binding to CD155 (PVR). By blocking TIGIT and PD-1, the combination seeks to overcome immune exhaustion and improve clinical outcomes in solid tumors, including extensive-stage small cell lung cancer (ES-SCLC), where it is being evaluated in Phase 3 trials (TIGOS) in combination with chemotherapy.
- Other names
- atigotatug/nivolumabnivolumab/atigotatug
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)Fuc-GM1 (Fucosyl-GM1 ganglioside)
Beyond the preview
Go deeper on atigotatug + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atigotatug + nivolumab.